Efficacy and Safety of MK-1654 in Infants (MK-1654-004)
Status:
Recruiting
Trial end date:
2025-01-08
Target enrollment:
Participant gender:
Summary
The primary objectives of this phase 2b/3 double-blind, randomized, placebo-controlled study
are to evaluate the efficacy and safety of MK-1654 in healthy pre-term and full-term infants.
It is hypothesized that MK-1654 will reduce the incidence of respiratory syncytial virus
(RSV)-associated medically attended lower respiratory infection (MALRI) from Days 1 through
150 postdose compared to placebo.